Form 4: Acrivon Therapeutics Chief Legal Officer Reports Stock Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On October 1, 2024, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., had 284 shares of common stock withheld by the issuer to satisfy tax obligations.
- The shares were withheld at a price of $6.98 per share.
- Following the transaction, Miller beneficially owns 38,683 shares of Acrivon Therapeutics, Inc.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, which is neutral to slightly positive as it indicates vesting of stock units.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider stock activity.
Key Dates
| Date | Description |
|---|---|
| 10/01/2024 | Date of stock transaction (tax withholding). |
| 10/03/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.